Alyeska Investment Group
PHAT icon

Alyeska Investment Group’s Phathom Pharmaceuticals PHAT Stock Holding History

Alyeska Investment Group’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-23,141
Closed -$721K – 452
2019
Q4 		$721K Buy
+23,141
New +$582K 0.01% 337

Other funds holding PHAT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Alyeska Investment Group's PHAT Position: Q1 2020 in Review

Alyeska Investment Group sold out of Phathom Pharmaceuticals (PHAT) in Q1 2020, closing a stake of 23,141 shares — an estimated $721K sold.

Alyeska Investment Group first reported a position in PHAT in Q4 2019 and held it in 1 quarter. The position peaked at $721K in Q4 2019. 47 funds tracked by Wall St. Rank hold PHAT as of Q1 2020.

  • Alyeska Investment Group reported no remaining Phathom Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Alyeska Investment Group sold 23,141 Phathom Pharmaceuticals shares in Q1 2020, an estimated $721K.
  • Alyeska Investment Group first reported a position in Phathom Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Alyeska Investment Group's Phathom Pharmaceuticals position peaked at $721K in Q4 2019.
  • 47 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2020.

Based on Alyeska Investment Group's 13F filing for Q1 2020, filed 15 May 2020.